Insulet Corporation (NASDAQ: PODD) — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited quarterly results; FY2016 Q4 revenue was $103.6 million and net loss was $9.1 million.
Business context
Insulet develops, manufactures and sells its tubeless Omnipod insulin delivery system and supplies on-body drug-delivery devices to pharmaceutical partners. In February 2016, it sold Neighborhood Diabetes and reports that business as discontinued operations. FY2016 revenue came from U.S. Omnipod, international Omnipod and drug delivery.
Financial highlights
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $367.0 million | $263.9 million | +39% |
| Gross profit / margin | $211.1 million / 57.5% | $133.3 million / 50.5% | Margin +7.0 percentage points |
| Operating loss | $10.7 million | $48.7 million | Loss narrowed |
| Net loss | $28.9 million | $73.5 million | Loss narrowed |
| Operating cash flow | $15.9 million provided | $12.6 million used | Improved |
Revenue by product line: U.S. Omnipod $229.8 million (+21%); international Omnipod $71.9 million (+78%); drug delivery $65.3 million (+92%). Gross-margin improvement reflected the absence of $11.5 million of costs incurred in 2015 and supply-chain efficiency gains. Operating expenses rose 22% to $221.8 million, including higher R&D and sales and marketing spending.
At year-end, cash and cash equivalents were $137.2 million, short-term investments $161.4 million, and working capital $314.3 million. Total assets were $456.6 million and stockholders’ equity $63.2 million. Long-term debt, net of discount and issuance costs, was $332.8 million; remaining note principal was $67.1 million on the 2% notes due 2019 and $345.0 million on the 1.25% notes due 2021. Investing cash outflow was $178.0 million, largely reflecting purchases of short-term investments; financing cash inflow was $176.6 million, principally from the new notes issuance.
Material changes and unusual items
- U.S. Omnipod growth followed expansion of the sales force and customer-support personnel; international growth reflected distributor sales and continued adoption.
- In September 2016, Insulet issued $345.0 million of 1.25% convertible notes and repurchased $134.2 million principal amount of its 2% notes for $153.6 million. The repurchase generated a $2.6 million debt-extinguishment loss.
- A $6.1 million Q4 charge in general and administrative expense related to in-process ERP software after the company revised its system plans.
- The Neighborhood Diabetes sale generated $6.2 million in cash, including closing adjustments. Its 2015 results included a $9.1 million impairment charge.
- In 2015, product-quality actions and related costs reduced gross margin, including $11.5 million of field-notification-related costs. The FDA terminated the 2015 field removal in January 2017; a separate field correction concerned increased reports of cannula deployment failure in certain lots.
Outlook, risks and contingencies
Management expected strong revenue growth across product lines in 2017 and approximately 20% growth in the worldwide Omnipod installed base. It expected gross margin to improve with further supply-chain efficiencies, but also projected higher R&D, sales and marketing, and general and administrative spending. Management expected continued net losses in the near term. It planned a highly automated U.S. manufacturing facility, targeting production in 2019, with capital spending above historical levels.
Management stated that cash, investments and expected sales proceeds should fund projected operating and debt-service requirements for at least 12 months. The filing also says liquidity was expected to cover operating requirements through at least the end of 2017. The company reported no substantial doubt about its ability to continue as a going concern.
Key risks include ongoing losses and uncertain profitability; reliance on Omnipod and third-party reimbursement; limited Medicare and broad Medicaid coverage for the system; competition and technological change, including competing hybrid closed-loop products; dependence on Flex and other suppliers, with production concentrated in China; execution and cost risks for the U.S. factory; product quality, regulatory and recall exposure; and customer/distributor concentration. Amgen and Ypsomed each accounted for more than 10% of revenue in 2016. One shareholder class action remained pending; the company said it could not reasonably estimate a possible loss. The filing reports no off-balance-sheet financing arrangements.
Important facts for investors to verify
- Whether 2017 revenue and installed-base growth targets were achieved, and whether growth translated into sustained positive operating cash flow and profitability.
- Whether gross-margin gains continued after the nonrecurring 2015 quality costs and whether manufacturing costs declined as planned.
- Progress, total cost and timing of the U.S. manufacturing facility, and continued supply reliability from Flex and other suppliers.
- Remaining convertible-note principal, conversion and dilution exposure, and the company’s capacity to service or refinance debt.
- Reimbursement developments, customer retention and concentration, product-quality performance, FDA compliance, and the outcome of the pending shareholder litigation.